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S UMM A R Y
S E T T I NG : The cost of multidrug-resistant tuberculosis
(MDR-TB) treatment is a major barrier to treatment
scale-up in South Africa.
OB J E C T I V E : To estimate and compare the cost of
treatment for rifampicin-resistant tuberculosis (RR-TB)
in South Africa in different models of care in different
settings.
DE S I GN : We estimated the costs of different models of
care with varying levels of hospitalisation. These costs
were used to calculate the total cost of treating all
diagnosed cases of RR-TB in South Africa, and to
estimate the budget impact of adopting a fully or
partially decentralised model vs. a fully hospitalised
model.
R E SU LT S : The fully hospitalised model was 42% more
costly than the fully decentralised model (US$13 432 vs.
US$7753 per patient). A much shorter hospital stay in
the decentralised models of care (44–57 days), compared
to 128 days of hospitalisation in the fully hospitalised
model, was the key contributor to the reduced cost of
treatment. The annual total cost of treating all diag-
nosed cases ranged from US$110 million in the fully
decentralised model to US$190 million in the fully
hospitalised model.
CON C L U S I ON : Following a more decentralised ap-
proach for treating RR-TB patients could potentially
improve the affordability of RR-TB treatment in South
Africa.
K E Y WORD S : MDR-TB; rifampicin-resistant tubercu-
losis; costing; budget impact; decentralization
LESS THAN 20% of the estimated number of
multidrug-resistant tuberculosis (MDR-TB) emerging
each year worldwide are diagnosed as such, and an
even smaller percentage receive appropriate second-
line treatment.1 The cost of MDR-TB treatment is a
major barrier to treatment scale-up in many settings,
with MDR-TB treatment estimated to cost around 26
times more than that for drug-susceptible TB.2 South
Africa has a high burden ofMDR-TB, with more than
14 000 cases notified in 2012.1 While scale-up of the
Xpertw MTB/RIF test (Cepheid, Sunnyvale, CA,
USA) has increased the case detection of rifampicin
(RMP) resistant TB (RR-TB) substantially since
2010, access to appropriate second-line treatment
has not kept pace. Routine data suggest that less than
half of diagnosed cases initiate second-line anti-
tuberculosis treatment.1 While data from the roll-
out of Xpert indicate that 7% of TB cases in South
Africa may have RR-TB,3 the cost of MDR-TB
treatment is reported to encompass close to 55% of
the total TB budget.1
The World Health Organization recommends
ambulatory models of care for drug-resistant anti-
tuberculosis treatment over hospital-based models.4
Before 2010, MDR-TB treatment was primarily
centralised in specialist TB hospitals with mandatory
in-patient admission. In 2011, faced with long
waiting lists for admission and treatment initiation,
the National Department of Health revised their
policy to support the decentralisation of MDR-TB
treatment.5 The revised policy removes the require-
ment to initiate treatment in hospital, but still
suggests that sputum smear-positive patients be
hospitalised. While the extent to which this policy
has been implemented across South Africa’s provinces
varies, the treatment gap for MDR-TB remains and
may be increasing as case detection improves with
Xpert.6
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Previous studies in South Africa have estimated the
cost of a centralised MDR-TB model of care.2,7
However, there is limited evidence on the impact of
introducing a decentralised model of care on both the
episode costs and the overall budget. Decentralisation
of MDR-TB treatment is likely to be less costly than a
fully hospitalised model, and can therefore potential-
ly improve the capacity to scale up treatment for all
diagnosed cases. We aimed to estimate the costs of
treatment for RR-TB in South Africa across a range of
models of care, based on the cost of treatment from a
decentralised programme in Cape Town.8 We also
estimated the likely budget impact of introducing
decentralised MDR-TB treatment across South Afri-
ca.
METHODS
Estimating the costs of the decentralised model of care
In 2007, a decentralised model for the management of
RR-TB was developed and piloted by Me´decins Sans
Frontie`res (MSF), the City of Cape Town and the
Provincial Government of the Western Cape (PGWC)
in Khayelitsha, the largest township in the Western
Cape Province. This model of care permits initiation
of treatment for RR-TB at primary health care clinics,
provided the patient is sufficiently clinically stable to
initiate MDR-TB treatment.9 The programme is
associated with improved case detection and treat-
ment initiation and results in treatment outcomes
comparable to those seen in centralised specialist
centres.8
Applying a cohort approach, we estimated the
mean episode cost of managing a RR-TB patient from
diagnosis to treatment outcome for each type of RR-
TB patient by multiplying the unit cost of each
treatment component by the number of times the cost
was incurred by each patient in the cohort. The
cohort included 467 RR-TB patients diagnosed and
treated in Khayelitsha during the period from January
2009 to December 2011. This included all patients
with a first episode of confirmed RR-TB for whom a
treatment outcome was known. Cost data for clinic
visits and hospital stay were collected from three
primary health care clinics, one step-down facility
and two TB hospitals. Sources of data included the
PGWC, the local equipment and furniture suppliers,
the Council for Scientific and Industrial Research for
building and maintenance costs, and interviews with
the facility manager. Where capital and overhead
resources were shared between MDR-TB and other
services, these joint clinic/hospital costs were allocat-
ed to MDR-TB on the basis of the proportion of total
visits/in-patient days for which the MDR-TB patient
accounted. Capital costs were annualised using a
discount rate of 3%, and the assumption that the
expected number of years of useful life was 20 years
for buildings and 10 years for equipment and
furniture.
The costs of diagnostic tests were estimated as part
of a wider study into Xpert introduction, the XTEND
study (Cunnama et al., paper in preparation). We
used published literature for monitoring tests during
treatment (Table 1).2 Drug costs were determined
Table 1 Unit cost components for all scenarios, 2013 (in US$)
Cost component
Unit cost
US$ Source
Clinic visit for initial diagnosis and monitoring 10.88 Study data
Clinic visit for direct drug collection/injections 4.89 Study data
In-patient day 71.61* Study data
Drugs† 2015.27 Study data
XpertW MTB/RIF 16.9 Cunnama (paper in preparation)
Microscopy tests 6.3 Cunnama (paper in preparation)
Sputum liquid culture 12.9 Cunnama (paper in preparation)
First-line DST (LPA) 20.3 Cunnama (paper in preparation)
Second-line DST 25.1 Cunnama (paper in preparation)
X-ray 24.01 Cunnama (paper in preparation)
Kidney test 12.45 Pooran2
Liver function test 17.24 Pooran2
TSH 23.94 Pooran2
Audiogram 29.28 Pooran2
HIV rapid screening test 6.03 Pooran2
CD4 count þ viral load 59.30 Pooran2
* In the base case, we used the average of US$71.61 but varied this estimate in a sensitivity analysis to factor in the
economies of scale in larger urban hospitals. The cost per in-patient day in a large urban hospital in Cape Town and a
smaller rural hospital in the Easter Cape was respectively US$44.44 and US$98.77.
† Treatment regimens: RMP-monoresistant and MDR-TB patients are treated with KM in the intensive phase, and MFX,
terizidone, ETH and pyrazinamide in both the intensive and continuation phases; pre-XDR fluoroquinolone patients are
given KM in the intensive phase, and MFX, terizidone, ETH, PAS and CFZ in both the intensive and continuation phases;
pre-XDR-TB INJ and XDR-TB patients use capreomycin in the intensive phase, and MFX, terizidone, ETH, PAS and CFZ in
both intensive and continuation phases.
DST ¼ drug susceptibility testing; LPA ¼ line-probe assay; TSH ¼ thyroid stimulating hormone; HIV ¼ human
immunodeficiency virus; KM¼kanamycin; MFX¼moxifloxacin; ETH¼ethionamide; PAS¼para-aminosalicylic acid; CFZ
¼ clofazimine; INJ¼ injection drug resistant; XDR-TB¼ extensively drug-resistant tuberculosis.
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using the Western Cape Central Medical Depot
tender price list, and computed based on the drug
resistance profile and the duration of the intensive
and continuation phases of treatment (Table 1).
Where required, data were inflated to 2013 rates
using the medical consumer price index of 6.4% for
2011 and 6.1% for 2012.10,11 Data were converted to
US dollars using the 2013 average annual exchange
rate of US$1 ¼ South African rand (ZAR) 9.3
(OANDA Currency Converter 2014. Average ex-
change rate for January–December 2013. http://
www.oanda.com).
Scenario analysis
Using the average treatment duration8 and the
average cost per patient treated from the cohort
analysis, but varying the duration of hospitalisation,
we estimated the cost per patient treated in different
models of care. The cost for each scenario assumed
that the proportion of clinically unwell patients
requiring hospitalisation was 19% (based on the
proportion of RMP-monoresistant and MDR-TB
cases who were hospitalised in the decentralised
model) and that 44% of patients are sputum smear-
positive (also based on the cohort data).
Four different potential scenarios for RR-TB
treatment provision were considered: a fully decen-
tralised model (as described for Khayelitsha above), a
fully hospitalised model, a partially decentralised
Model A and a partially decentralisedModel B. In the
fully hospitalised model, all patients are admitted to
hospital until culture conversion (4 months), with
long-term admission for extensively drug-resistant TB
(XDR-TB) patients. Models A and B were based on
recommendations from 2011 South African national
policy5 and previously described models of care in
South Africa.12,13 South African policy suggests that
patients who are sputum smear-positive or have
XDR-TB require admission for treatment initiation
until two consecutive smear-negative results have
been received. Alternative models of decentralised
care describe short periods of hospitalisation of
around 2 weeks at treatment initiation for the
majority of patients, to ensure that the patients are
stabilised on second-line medications.12
In the partially decentralised Model A, all patients
are admitted for 2 weeks to initiate treatment, while
the partially decentralised Model B required all
sputum smear-positive patients to be hospitalised
for 8 weeks or until smear conversion. In all models of
care, once discharged from hospital, all patients were
treated at clinic level.
Estimation of total costs of different models across
nine provinces in South Africa
We estimated the total cost of treating all diagnosed
cases of RR-TB in South Africa, and the contribution
of hospitalisation to this cost using each scenario. As
different scenarios may be more appropriate in
different settings or different provinces in South
Africa, we considered an additional scenario using
the urban/rural population ratio per province and
then applying this ratio to the number of diagnosed
MDR-TB cases in each province. To assess variability,
we used the 95% confidence intervals (CIs) for the
average length of hospitalisation to vary the estimates
of costs of treatment across the different scenarios.
Sensitivity analysis
Five univariate sensitivity analyses were performed.
The first analyses address uncertainty in the cohort
population.We also examined our assumptions about
the models of care, in particular the ability to provide
all out-patient visits at a fixed site and accessibility of
hospital care. Lastly, we used a different cost of in-
patient day to accommodate the economies of scale
applicable in larger, urban specialised TB hospitals
(we assumed that the economies of scale are not
relevant at the primary care level).
Ethics statement
Ethics approval was not required for this study as it
did not involve the participation of human subjects.
RESULTS
Cohort description
Among the cohort, 72% of patients were human
immunodeficiency virus (HIV) infected. The average
treatment duration was 482 days (95%CI 457–507),
with 169 days (95%CI 143–195) of intensive phase
treatment. The average length of hospitalisation at
admission and during treatment was respectively 36
days (95%CI 29–42) and 8 days (95%CI 4–12).
Overall treatment success was 49%, with 30%
default.
Cost of treatment in different models of care
Based on the cohort costing, the average cost of
treatment for RR-TB, combining all types of RR-TB
patients in the decentralised model, was US$7753.
The average costs of managing a RR-TB patient in
different models are shown in Table 2. The fully
hospitalised model was 42% more costly than the
fully decentralised model. Partially decentralised
Models A and B are also lower-cost models of care
than the fully hospitalised model. A much shorter
period of hospitalisation in the decentralised models
of care, ranging from 44 to 57 days, compared to 128
days of hospitalisation in the fully hospitalised model,
was the key contributor to the reduced cost of
treatment.
Overall budget impact
The total cost of treating all 14 161 diagnosed cases
of RR-TB in 2012 in South Africa ranged from
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US$110 million in the fully decentralised model to
US$190 million in the fully hospitalised model of care
(Table 3). This translated to 23–40% of the 2013
total National Tuberculosis Programme (NTP) bud-
get, and 42–73% of the total MDR-TB budget.
Following a more decentralised approach for treating
RR-TB patients could potentially reduce the costs by
15–32% (Figure). The urban-rural scenario could
also potentially reduce the cost of treatment by 14%
at the national level (Table 4). This scenario will have
a larger impact in the more urban provinces such as
Gauteng, the Western Cape and the Free State, where
higher proportions of the population live in urbanised
areas.
Sensitivity analysis
Varying the proportion of sputum smear-positive
patients in Model B resulted in relatively small
impacts of ,5% of the total cost of treatment in that
model of care (Table 5). If clinic visits for drug
collection in Model A were replaced by home visits,
the cost of treatment went up by 22%; however, total
cost remained lower than with fully centralised care.
The impact of the lower/upper cost of in-patient day
on the total cost of treatment depended on the extent
to which patients were hospitalised in each model. In
the urban-rural scenario, replacing the fully hospital-
ised model with the partially decentralised Models A
and B reduced the total cost of treatment by
respectively 31% and 29%. The sensitivity analysis
showed 17% higher/3% lower total costs for all
scenarios when the relative proportion of XDR-TB
and pre-XDR-TB patients was doubled/halved.
DISCUSSION
We observed that the introduction of decentralised
treatment in South Africa may reduce the overall cost
to the NTP by between approximately 15% and 18%
of the NTP budget, depending on the model adopted
and on different assumptions about the characteris-
tics of the MDR-TB patient cohort. Given that the
overall cost of RR-TB treatment will likely increase
with Xpert-driven increases in case detection,15 cost
savings that could be achieved through the imple-
mentation of more decentralised treatment could
absorb these increased overall costs. Moreover, a
decentralised model of care has been shown to be as
effective as a fully hospitalised model of care, and
may improve patient access.9,12 Other benefits
Table 2 Costs of managing a drug-resistant tuberculosis patient from diagnosis to completion of treatment, different scenarios,
2013 (in US$)
Fully decentralised
US$ (95%CI)
Fully hospitalised
US$ (95%CI)
Partially decentralised
Model A*
US$ (95%CI)
Partially decentralised
Model B†
US$ (95%CI)
Clinic visits for diagnosis and
monitoring 174 (152–207) 131 (109–163) 174 (152–207) 152 (130–185)
Clinic visits for drug
collection and injections 1530 (1481–1582) 1236 (1222–1411) 1509 (1467–1558) 1484 (1446–1526)
Hospital stay‡ 3151 (2363–3867) 9166 (6875–11243) 3580 (2650–4368) 4082 (3079–5013)
Drugs 2015 2015 2015 2015
Diagnostic and monitoring
tests 883 883 883 883
Total§ 7753 (6917–8522) 13 432 (11 165–15494) 8162 (7189–8999) 8617 (7576–9590)
*Admission for all patients for 2 weeks to initiate treatment, extended hospitalisation for the proportion who were clinically unwell and ambulatory treatment for
the rest.
† Admission for all smear-positive patients for treatment initiation for 8 weeks, extended hospitalisation for a proportion who are clinically unwell and ambulatory
treatment for the rest.
‡ ALOS was calculated for each scenario based on the Khayelitsha patient cohort data: for a fully decentralised model, ALOS ¼ 44 hospital days (36 days at
admissionþ 8 days during treatment); for a fully hospitalised model, ALOS¼ 128 hospital days (120 days at admissionþ 8 days during treatment); for Model A,
ALOS¼ 50 days (42 days at admissionþ 8 days during treatment); and for Model B, ALOS¼ 57 days (49 days at admissionþ 8 days during treatment).
§Mean treatment duration of 482 (95%CI 457–507) was the same for all scenarios.
ALOS¼ average length of stay; CI¼ confidence interval.
Table 3 Total cost of treatment for all patients diagnosed and treated in South Africa in 2012 and the associated proportion of the
budget spent in different scenarios, 2013 (in US$)
Fully decentralised
US$
Fully hospitalised
US$
Partially decentralised Model A
US$
Partially decentralised Model B
US$
Cost for all diagnosed cases* 109794198 190208003 115584975 122029079
Proportion of total NTP budget† 23 40 24 26
Proportion of MDR-TB budget‡ 42 73 44 47
*There were 14 161 cases diagnosed in 2012.14
† 2013 budget (WHO 2013).1
‡ Using the 2010 and 2011 budget figures, 55% of the 2013 total NTP budget was allocated to MDR-TB (WHO 2013).1
NTP¼National Tuberculosis Control Programme; MDR-TB¼multidrug-resistant tuberculosis; WHO¼World Health Organization.
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include earlier treatment initiation, resulting in
improved early mortality and theoretically reduced
community transmission.
Our episode cost findings are based on sound
cohort data, and our unit and episode costs are
consistent with previous cost analyses of MDR-TB
treatment in South Africa ranging from US$6772 to
US$17 164 between decentralised and fully hospital-
ised models.2,7 Nevertheless our estimates have some
limitations. First, we focused on the efficiency in the
delivery of RR-TB treatment in different models of
care and did not consider the hospital capacity for
each model. In high-burden settings, the bed capacity
required even for Models A and B may not be
feasible. In this analysis, we only included health
service costs and did not consider costs borne by RR-
TB patients, which may vary with different models of
care. We are currently undertaking an RR-TB patient
cost analysis to complement this study. We did not
include the cost of home visits in our estimates, as
home visits are not part of the Khayelitsha model.8
However, we added the cost of home visits in one of
our sensitivity analyses (Table 5, Model A). Finally,
there remains some uncertainty about the number of
RR-TB cases diagnosed. In the absence of a system to
record all diagnosed cases, notifications rely on
laboratory data, which may lead to an overestimation
of the number of cases diagnosed due to duplicate
results for the same patient.
One of the study findings was that the cost between
the decentralised models of care is very similar, and
that, therefore, from the cost perspective, different
approaches to decentralisation could be applied in
different settings. A fully decentralised model is
appropriate in high-burden, urban areas with an
existing infrastructure (e.g., staff available to be
trained on RR-TB treatment), where clinics have the
capacity to increase the workload and where hospi-
talisation is required only for those patients who are
clinically unwell. Hospitals could be used for patients
who are not doing well on treatment and those in
whom treatment is failing. This includes a consider-
able proportion of XDR-TB patients, although those
who do respond to treatment can be treated on an
ambulatory basis. In addition, there are some settings
with low population density and low RR-TB burden
that may be more suited to a model of care with more
hospitalisation to enable patients to receive an
Figure Potential cost savings through reduced hospital stay, different scenarios. NTP¼ National Tuberculosis Control Programme;
MDR-TB¼multidrug-resistant tuberculosis.
Table 4 Total cost of treatment for all diagnosed patients assuming different models of care for urban and rural populations, per
province, 2013 (US$)
Province
% urban/rural
population
Diagnosed
MDR-TB cases
n
Total cost: fully
decentralised model
US$
Total cost: fully
hospitalised model
US$
Total cost:
% urban fully
decentralised
and % rural
fully hospitalised
US$
Eastern Cape 36.6/63.4 2 205 17095982 29617163 25034414
Free State 68.6/31.4 390 3023779 5 238410 3918238
Gauteng 97.0/3.0 1 198 9228429 16091320 8795179
KwaZulu-Natal 43.1/56.9 6 630 51404246 89052967 82714173
Mpumalanga 39.1/60.9 266 2062372 3 572864 3419898
Northern Cape 70.1/29.9 760 5892493 10208183 7521590
Limpopo 11.0/89.0 373 2891973 5 010069 5793957
North West 34.9/65.1 267 2070126 3 586296 3539572
Western Cape 88.9/11.1 2 072 16064796 27830731 16810363
South Africa 53.7*/46.3 14161 109794198 190208003 162370737
* In 2011, 62% of South Africa’s population was urban. However, the estimates for provinces were not available.
MDR-TB¼multidrug-resistant tuberculosis.
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appropriate standard of care. However, in all models
of care, appropriate referral management systems
between hospitals and primary care services are
required to maintain continuity of care and ensure
that patients are supported. Different models of care
with different cost profiles may therefore be needed to
enable all RR-TB patients to receive treatment.
Model A seems appropriate in remote, rural settings,
where it may be more advantageous to initiate
treatment in hospital for the majority of patients for
2 weeks. Finally, Model B could be implemented in a
TB unit as part of a district hospital, with only very
complicated patients referred to a specialised TB
hospital. Decentralised models of care in high-burden
rural areas can achieve further cost savings by using
both clinic and home visits, depending on the
patient’s proximity to their nearest clinic. From the
patient’s perspective, models of care that provide
more flexibility may be more suitable.
Potential difficulties with more widespread imple-
mentation of decentralised care need to be acknowl-
edged. The capacity to treat the increasing number of
patients in a clinic setting may be lacking in some
areas, particularly in rural areas struggling to retain
staff and allocate resources effectively. Clinic staff
will need to be trained in RR-TB treatment manage-
ment, with ongoing supervision. Training might
require additional resources in terms of staff time
away from their usual activities and transport. Strong
referral systems for complicated cases, along with
good systems for data recording and reporting, are
also required.
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R E S UM E
CONT EX T E : Le couˆt du traitement de la tuberculose
(TB) multire´sistante est une contrainte majeure a`
l’expansion du traitement en Afrique du Sud.
OB J E C T I F : Estimer et comparer le couˆt du traitement
de la TB re´sistante a` la rifampicine (RR-TB) en Afrique
du Sud dans diffe´rents mode`les de soin et diffe´rents
contextes.
S CH E´MA : Nous avons estime´ le couˆt des diffe´rents
mode`les de soins avec des niveaux variables
d’hospitalisation. Ces calculs ont permis d’estimer le
couˆt total du traitement de tous les cas diagnostique´s de
RR-TB en Afrique du Sud et d’estimer l’impact
budge´taire de l’adoption totale ou partielle d’un
mode`le de´centralise´ contre un mode`le hospitalier.
R E´ S U LTAT S : Le mode`le hospitalier a e´te´ plus cher de
42% que le mode`le totalement de´centralise´ (13 432$US
contre 7753$US par patient). La re´duction du couˆt du
traitement e´tait surtout lie´e a` un temps d’hospitalisation
beaucoup plus court dans le mode`le de soin de´centralise´
(44–57 jours) compare´ a` 128 jours d’hospitalisation
dans le mode`le pleinement hospitalier. Le couˆt annuel
total du traitement de tous les cas diagnostique´s allait de
110 millions de $US dans le mode`le pleinement
de´centralise´ a` 190 millions de $US dans le mode`le
totalement hospitalier.
CONC LU S I ON : Une approche plus de´centralise´e du
traitement des patients RR-TB aurait le potentiel de
rendre le traitement de la RR-TB plus abordable en
Afrique du Sud.
R E S UM E N
MARCO DE R E F E R ENC I A: El costo del tratamiento de la
tuberculosis (TB) multidrogorresistente constituye el
principal obsta´culo a la ampliacio´n de escala del
tratamiento en Sura´frica.
O B J E T I V O: Calcular y comparar el costo del
tratamiento de la TB resistente a rifampicina (RR-TB)
en Sura´frica, con diversos modelos de atencio´n en
diferentes entornos.
M E´ TODO: Se calcularon los costos segu´n varios modelos
de atencio´n con diferentes estrategias de hospitalizacio´n.
Estos costos se usaron con el fin de calcular el costo total
del tratamiento de todos los casos de RR-TB
diagnosticados en Sura´frica y estimar las repercusiones
que tendrı´a en el presupuesto, la adopcio´n de un modelo
de tratamiento totalmente hospitalario en comparacio´n
con modelos de tratamiento parcial o totalmente
descentralizado.
R E S U LTA DO S: El modelo de atencio´n enteramente
hospitalaria fue 42% ma´s costoso que un modelo
totalmente descentralizado (13 432USD contra
7753USD por paciente). Una hospitalizacio´n mucho
ma´s corta en los modelos descentralizados de atencio´n
(de 44–57 dı´as), en comparacio´n con 128 dı´as en el
modelo enteramente hospitalario, fue el factor que ma´s
contribuyo´ a disminuir los costos del tratamiento. El
costo anual total del tratamiento de todos los casos
diagnosticados oscilo´ entre 110USD millones en el
modelo totalmente descentralizado y 190USD millones
en el modelo de tratamiento exclusivamente
hospitalario.
CONC LU S I O´ N: La aplicacio´n de una estrategia ma´s
descentralizada del tratamiento de la RR-TB podrı´a
mejorar la viabilidad econo´mica del tratamiento de estos
casos en Sura´frica.
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